Mylan NV has developed an impressive pipeline of biosimilars, but whether it can turn those products into commercial successes on the big stage that is the US market remains a question. Now, after many years of investment, the company seems close to getting the chance to launch its first biosimilar in the US, a version of Amgen Inc.'s Neulasta (pegfilgrastim).
Mylan showcased its biosimilar pipeline during an investor day in New York City April 11. The company has 11 biosimilar...








